Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
Cabaletta Bio at a Crossroads - Buy the Pullback or Respect the Burn?
Clinical-stage CAART specialist; attractive low market cap but high binary clinical risk. Trade the thesis with tight risk controls.
Cabaletta Bio (CABA) is a clinical-stage cell therapy company developing CAART/CARTA approaches for B cell-mediated autoimmune diseases. The stock is ...
Advanced Energy (AEIS) - Position Trade: 2026 Growth Acceleration Priced In, But Not Guaranteed
Q3 2025 momentum and margin expansion set the stage for an accelerated growth year in 2026; enter on weakness with clear stops and targets.
Advanced Energy reported accelerating revenue and margin expansion into Q3 2025, driven by strength in semiconductor and data-center end markets. Oper...
Expedia Still Looks Worth the Price: Earnings, Margins and a Path Higher
Strong Q3 2025 results and durable cash generation justify a constructive trade — buy the pullback, target the next leg up.
Expedia (EXPE) reported a strong Q3 2025 where revenue and operating income expanded materially. The stock’s recent rally is backed by improving mar...
PVH: Discounted Enough – Low Multiple Prices In A Turnaround
5.7x P/E, improving margins, and manageable leverage create a tactical long opportunity with a clear risk plan.
PVH shares trade near $61.50, implying a 5.7x P/E. Recent quarters show operating improvement at Calvin Klein and Tommy Hilfiger, a cleaner brand port...
Western Alliance (WAL): Q4 Beat Confirms Momentum - Upgrade to Long (Swing)
Earnings beat, improving revenue mix and asset growth give conviction; tradeable setup with defined entry, stop and targets.
Western Alliance reported a solid Q4 that beat top- and bottom-line expectations and continues a multi-quarter trend of rising net income, assets and ...
TSLA: Betting on Robotaxis and TAAS - Position Trade with Defined Entry, Stop and Targets
Autonomy + fleet monetization can re-rate Tesla's multiple; buy the structural optionality with a position-sized long.
Tesla's near-term financials show healthy cash flow and improving gross profit while the company deploys the critical pieces for Transport-as-a-Servic...
Arista Networks: Riding the AI Data Center Upgrade - A Tactical Long
High margins, hyperscaler exposure, and GPU attach rates support a near-term growth rerate — but valuation and competition matter.
Arista is the networking backbone for modern AI data centers. Recent quarters show accelerating revenue and industry-leading margins, driven by high-s...
Clover Health: Buy the 2026 Profit Breakout Story at Deep Value Levels
Sequential premium revenue growth, improving operating cash flow and a clean balance sheet set up a path to profitability — entry at $2.35, stop $1.80, targets $3.50/$5.00.
Clover Health (CLOV) looks materially undervalued today. Revenue is growing sequentially, operating cash flow has flipped positive in recent quarters,...
Buy the Balance Sheet, Not the Bet - Tactical Apple (AAPL) Long With Guardrails
Valuation looks compelling on cash flow and buybacks; I remain skeptical about the companys newest product technology direction.
Apple looks like a structurally safe name to own from a corporate-finance standpoint - roughly $3.9T market cap, strong operating cash flow and contin...
Qiagen: High-Quality Consumables Platform with Real Takeover Optionality
Play durable consumables + potential M&A premium — tactical long with defined entry, stop and two targets.
Qiagen (QGEN) runs a sticky consumables-first business (≈90% of sales) with a broad footprint (Americas 52%, EMEA 33%, APAC 15%) and recent M&A chat...
Energy Transfer - Focus the Trade on Operating Cash, Not the Headline Yield
A tactical long that pays you to wait while operations and DCF recover clarity
Energy Transfer (ET) offers a high dividend yield and steady operating cash flow, but the stock trades at distressed-looking prices because investors ...
REGENXBIO Ahead of FDA Hunter Syndrome Decision - A High-Risk, Asymmetric Swing Trade
Approval decision in weeks makes RGNX a binary setup; pick your exposure and manage cash-burn risk
REGENXBIO (RGNX) faces a coming FDA decision on its gene therapy for Hunter syndrome. The stock is priced for outcomes; the company's balance sheet an...